Concepts (66)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2021 | 63 | 1.03 | Why? |
| Therapies, Investigational | 1 | 2020 | 235 | 0.71 | Why? |
| Periodontitis | 1 | 2018 | 171 | 0.60 | Why? |
| Protein-Arginine Deiminases | 3 | 2018 | 12 | 0.56 | Why? |
| Arthritis, Rheumatoid | 5 | 2018 | 2043 | 0.55 | Why? |
| Aggregatibacter actinomycetemcomitans | 2 | 2018 | 8 | 0.38 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.37 | Why? |
| Autoantibodies | 5 | 2018 | 2094 | 0.34 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.29 | Why? |
| Hydroxychloroquine | 3 | 2020 | 12447 | 0.23 | Why? |
| Autoimmunity | 2 | 2018 | 841 | 0.21 | Why? |
| Pasteurellaceae Infections | 1 | 2018 | 9 | 0.19 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.18 | Why? |
| Arthritis | 1 | 2021 | 288 | 0.16 | Why? |
| Rheumatologists | 1 | 2020 | 346 | 0.16 | Why? |
| Sarcoidosis | 1 | 2018 | 271 | 0.14 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.11 | Why? |
| Public Opinion | 1 | 2020 | 1165 | 0.10 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.07 | Why? |
| Pneumonia, Viral | 5 | 2021 | 243684 | 0.07 | Why? |
| Rheumatic Diseases | 1 | 2021 | 2675 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.06 | Why? |
| Doxazosin | 1 | 2021 | 27 | 0.06 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.05 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Silicon Dioxide | 1 | 2018 | 131 | 0.04 | Why? |
| Histocompatibility Testing | 1 | 2018 | 219 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Humans | 13 | 2021 | 930598 | 0.04 | Why? |
| Dust | 1 | 2018 | 178 | 0.04 | Why? |
| Cross Reactions | 2 | 2018 | 4374 | 0.04 | Why? |
| Antigens, Bacterial | 1 | 2018 | 330 | 0.04 | Why? |
| Promoter Regions, Genetic | 1 | 2018 | 823 | 0.03 | Why? |
| Sweden | 1 | 2021 | 1969 | 0.03 | Why? |
| Antibody Affinity | 1 | 2017 | 1078 | 0.03 | Why? |
| Middle Aged | 5 | 2021 | 270681 | 0.03 | Why? |
| Aged | 4 | 2021 | 215776 | 0.03 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.03 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Male | 5 | 2021 | 367725 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2018 | 4002 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Female | 3 | 2020 | 380317 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2018 | 4849 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Immunosuppressive Agents | 1 | 2021 | 6331 | 0.01 | Why? |
| Communication | 1 | 2020 | 5206 | 0.01 | Why? |
| Adult | 1 | 2020 | 244371 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |